RVMD
Revolution Medicines, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -9.1% ·
share flow -6.9% ·
net new positions -10.0%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 149 | +17 | 106.81M | $18.63B | +25 | −7 |
| Q1 2026 | 134 | +17 | 103.45M | $9.43B | +22 | −6 |
| Q4 2025 | 116 | +1 | 107.70M | $8.12B | +3 | −1 |
| Q3 2025 | 20 | +3 | 68.96M | $3.10B | +3 | −1 |
| Q2 2025 | 15 | 0 | 63.88M | $2.26B | — | — |
| Q1 2025 | 12 | +2 | 32.32M | $1.05B | +2 | — |
| Q4 2024 | 10 | -1 | 33.19M | $1.34B | — | −1 |
| Q3 2024 | 10 | -1 | 26.28M | $1.08B | — | −1 |
| Q2 2024 | 11 | — | 28.23M | $999.53M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 11.40M | -16.5% | $517.05M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 2 | Wellington Management ✦ | 11.40M | -16.5% | $517.05M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 3 | Wellington Management ✦ | 11.40M | -16.5% | $517.05M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 4 | Wellington Management ✦ | 11.40M | -16.5% | $517.05M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 5 | Wellington Management ✦ | 11.40M | -16.5% | $517.05M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 6 | Wellington Management ✦ | 11.40M | -16.5% | $517.05M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 7 | Wellington Management ✦ | 11.40M | -16.5% | $517.05M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 8 | Wellington Management ✦ | 11.40M | -16.5% | $517.05M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 9 | T. Rowe Price ✦ | 5.92M | +1.7% | $241.04M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 5.92M | +1.7% | $241.04M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | T. Rowe Price ✦ | 5.92M | +1.7% | $241.04M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Geode Capital Management ✦ (passive) | 3.63M | +8.7% | $164.52M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 13 | Geode Capital Management ✦ (passive) | 3.63M | +8.7% | $164.52M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 14 | Norges Bank ✦ (passive) | 1.75M | -5.5% | $79.21M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | Marshall Wace ✦ | 1.06M | +30.5% | $48.30M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 16 | Adage Capital Partners ✦ | 790.00K | +17.9% | $13.22M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 17 | Adage Capital Partners ✦ | 790.00K | +17.9% | $13.22M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 18 | Citadel Advisors ✦ | 304.60K | -30.6% | $12.74M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 19 | Citadel Advisors ✦ | 304.60K | -30.6% | $12.74M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 20 | D. E. Shaw & Co. ✦ | 1.39M | +0.8% | $2.00M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 21 | D. E. Shaw & Co. ✦ | 1.39M | +0.8% | $2.00M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 22 | D. E. Shaw & Co. ✦ | 1.39M | +0.8% | $2.00M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 23 | Two Sigma Investments ✦ | 22.89K | +0.6% | $1.04M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 24 | AQR Capital Management ✦ | 15.25K | +18.8% | $691,452 | 0.0% | ▲ Add | 2 | SEC ↗ |
| 25 | AQR Capital Management ✦ | 15.25K | +18.8% | $691,452 | 0.0% | ▲ Add | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Point72 Asset Management | $8.85M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 13.50K shares, $1,312 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 3.40K sh · $704,603
Officer · 17.32K sh · $3.61M
Officer · 25.82K sh · $5.40M
Officer · 2.54K sh · $534,072
Officer · 4.50K sh · $951,038
Officer · 3.31K sh · $702,761
Officer, Director · 5.13K sh · $1.06M
Officer, Director · 24.92K sh · $5.19M
Officer, Director · 35.94K sh · $7.52M
Officer, Director · 3.81K sh · $801,670
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology